Price exploration of Apelvis in Bangladesh market

Alpelisib, an anti-tumor drug carefully developed by Novartis, has become a shining star in the field of breast cancer treatment due to its unique inhibitory effect on phosphatidylinositol-3 kinase (PI3K). By precisely inhibiting PI3Kα (PIK3CA) activity, it effectively promotes the transcription of estrogen receptors in breast cancer cells, thus opening up a new way to fight tumors. Not only that, Apelvis has also received authoritative certification from the U.S. Food and Drug Administration (FDA), becoming an important weapon in the treatment of specific types of advanced metastatic breast cancer in combination with fulvestrant.

However, for the market in Bangladesh, the price of Apelvis has always been a focus of concern for patients and the medical community. As we all know, there is a certain gap between Bangladesh and the international advanced level in terms of drug supervision, production technology and quality control. Therefore, there is no official sale of the original or generic version of Apelvis in the Bangladeshi market. This situation makes patients in Bangladesh face many challenges when seeking treatment with Apelvis.

In addition, it is worth noting that the original version of Apelis has been marketed in overseas markets such as Europe and India. These versions of the drug differ in specifications, with common specifications including 150mg 56 tablets per box and 150mg 28 tablets per box. In terms of price, affected by various factors such as exchange rate fluctuations, the price of each box of Apelis may fluctuate between 5,000 and more than 40,000 yuan. At the same time, generic drugs of Apelvis are also on the market in some overseas countries. These generic drugs are highly similar to the original drugs in terms of pharmaceutical ingredients and are relatively more affordable. For example, the price of a 150mg*28 tablet generic drug produced by Lucius Pharmaceutical Factory in Laos may be around RMB 2,000.